Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · Real-Time Price · USD
2.260
-0.050 (-2.16%)
Jun 25, 2026, 3:10 PM EDT - Market open
Acumen Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
61
Market Cap
163.23M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Protalix BioTherapeutics | 76.38M |
| Precision BioSciences | 45.07M |
| LENZ Therapeutics | 20.99M |
| MediWound | 14.48M |
| Innate Pharma | 10.57M |
| Equillium | 4.39M |
| Milestone Pharmaceuticals | 1.78M |
ABOS News
- 8 days ago - JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform - Business Wire
- 9 days ago - Acumen nominates two development candidates in EBD program - TheFly
- 9 days ago - Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer's Disease - GlobeNewsWire
- 6 weeks ago - Acumen Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 6 weeks ago - Acumen Pharmaceuticals Earnings Call Transcript: Q1 2026 - Transcripts
- 6 weeks ago - Acumen Pharmaceuticals Earnings release: Q1 2026 - Filings
- 6 weeks ago - Acumen Pharmaceuticals Quarterly report: Q1 2026 - Filings
- 6 weeks ago - Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights - GlobeNewsWire